NCT03316573 2026-02-10Pembrolizumab in Neoplasms or LymphomasDana-Farber Cancer InstitutePhase 2 Suspended18 enrolled 16 charts
NCT02523040 2025-12-10Lenalidomide for Adult Histiocyte DisordersDana-Farber Cancer InstitutePhase 2 Active not recruiting12 enrolled 14 charts
NCT06712810 2025-10-10Q702 for the Treatment of Patients With Hematologic MalignanciesMayo ClinicPhase 1 Recruiting46 enrolled
NCT05915208 2025-06-11Histiocytic Disorder Follow-up StudyUniversity of Alabama at BirminghamRecruiting6,000 enrolled